Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.

ABSTRACT: BACKGROUND:Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with non-squamous non-small cell lung carcinoma (NSCLC) has significantly improved outcome in this cohort. Preclinical and early clinical data suggest that the combination of photon radiation with programmed death-1 (PD-1) targeting immunotherapies may promote a strong and durable immune response against tumor manifestations both within and beyond radiation targets. METHODS/DESIGN:In the present prospective, two-group, non-randomized, open-label phase II trial, 130 patients with stage IV non-squamous

SUBMITTER: Bozorgmehr F 

PROVIDER: S-EPMC6842256 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature